Item 2.01 Completion of Acquisition of Disposition of Assets

On November 1, 2019, Aytu BioScience, Inc. ("Company") and Cerecor, Inc. ("Seller") closed the acquisition (the "Acquisition") of the Pediatrics Product Portfolio (the "Cerecor transaction") contemplated by the Purchase Agreement. Pursuant to the Purchase Agreement, Seller transferred certain assets and assigned certain liabilities to a newly formed subsidiary established by the Company to hold the assets which are the subject of the Purchase Agreement, Aytu Therapeutics, LLC ("Aytu Therapeutics"). In addition, the Seller transferred most of its existing commercial sales workforce to the Company.

The Company determined that this acquisition constitutes a business pursuant to Article 11 of Regulation S-X, and therefore is required pursuant to Rule 8-04 of Regulation S-X to provide within 71 days after the Acquisition close, historical, audited financial statements for a period consisting of the most recent fiscal year ended December 31, 2018 and the nine months ended September 30, 2019. In addition, pursuant to Article 11 of Regulation S-X, the Company is required to provide pro forma financial statements for the year-ended June 30, 2019 and three months ended September 30, 2019.

The exhibits to this amended Form 8-K satisfies these requirements.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of businesses acquired

The (i) audited historical abbreviated financial statements for the Pediatrics Product Portfolio of Cerecor, Inc. (the "Cerecor Products") as of September 30, 2019, and December 31, 2018 and for the Nine Months Ended September 30, 2019 and the Year Ended December 31, 2018, and (ii) unaudited historical abbreviated financial statements for the Cerecor Products. as of September 30, 2018 and for the Nine Months Ended September 30, 2018 is filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K/A.

Pursuant to a letter dated October 21, 2019 (the "Relief Letter"), the Company has obtained relief from the Staff of the Securities and Exchange Commission, pursuant to its authority under Rule 3-13 of Regulation S-X, from the requirements of Rule 8-04 of Regulation of S-X to provide certain historical financial statements that would otherwise be required in connection with its acquisition of the Cerecor Products and to provide corresponding pro forma financial information required under Article 11 of Regulation S-X. In accordance with the Relief Letter, the Company has substituted abbreviated audited historical financial statements for the full financial statements of Cerecor Products required by Rule 8-04 of Regulation S-X.

(d) The following exhibit is being filed herewith:





Exhibit   Description
23.1        Consent of Ernst & Young LLP, independent auditors of the abbreviated
          financial statements of the Pediatrics Product Portfolio of Cerecor,
          Inc.
99.1        Audited historical abbreviated financial statements for the Pediatrics
          Product Portfolio of Cerecor, Inc. as of September 30, 2019, and December
          31, 2018 and for the Nine Months Ended September 30, 2019 and the Year
          Ended December 31, 2018.
99.2        Unaudited historical abbreviated financial statements for the
          Pediatrics Product Portfolio of Cerecor, Inc. as of September 30, 2018
          and for the Nine Months Ended September 30, 2018.
99.3        Unaudited pro forma condensed combined Balance Sheet as of June 30,
          2019 and Statement of Operations for the year ended June 30, 2019 and
          three months ended September 30, 2019 for the combination of (i) Aytu
          BioScience, Inc., (ii) the Cerecor transaction and (iii) the proposed
          merger with Innovus Pharmaceuticals, Inc.




                                       1

© Edgar Online, source Glimpses